Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dermatology | 19 | 2024 | 918 | 4.430 |
Why?
|
Skin Diseases | 15 | 2024 | 1095 | 1.840 |
Why?
|
Stevens-Johnson Syndrome | 5 | 2023 | 246 | 1.180 |
Why?
|
Acute Generalized Exanthematous Pustulosis | 3 | 2022 | 14 | 1.140 |
Why?
|
Telemedicine | 6 | 2024 | 3051 | 0.980 |
Why?
|
Papillomavirus Vaccines | 2 | 2020 | 496 | 0.900 |
Why?
|
Dermatitis | 3 | 2022 | 202 | 0.870 |
Why?
|
Epidermodysplasia Verruciformis | 1 | 2023 | 22 | 0.850 |
Why?
|
Skin Abnormalities | 1 | 2022 | 60 | 0.810 |
Why?
|
Purpura | 1 | 2022 | 117 | 0.790 |
Why?
|
Exanthema | 3 | 2022 | 503 | 0.790 |
Why?
|
Referral and Consultation | 8 | 2022 | 3608 | 0.780 |
Why?
|
Pyoderma Gangrenosum | 3 | 2021 | 84 | 0.760 |
Why?
|
Skin | 10 | 2024 | 4473 | 0.760 |
Why?
|
Scabies | 1 | 2020 | 14 | 0.730 |
Why?
|
Appointments and Schedules | 2 | 2024 | 442 | 0.730 |
Why?
|
Prisoners | 1 | 2024 | 314 | 0.720 |
Why?
|
Pemphigus | 1 | 2021 | 107 | 0.710 |
Why?
|
Salicylic Acid | 1 | 2020 | 62 | 0.680 |
Why?
|
Warts | 1 | 2020 | 66 | 0.670 |
Why?
|
Skin Neoplasms | 5 | 2022 | 5809 | 0.670 |
Why?
|
Cryptococcus neoformans | 1 | 2020 | 120 | 0.660 |
Why?
|
Cryptococcosis | 1 | 2020 | 103 | 0.660 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2020 | 85 | 0.650 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2021 | 212 | 0.650 |
Why?
|
Cnidarian Venoms | 1 | 2019 | 19 | 0.650 |
Why?
|
Drug Eruptions | 4 | 2022 | 335 | 0.630 |
Why?
|
Immunoglobulins, Intravenous | 2 | 2020 | 668 | 0.630 |
Why?
|
Medical Records | 1 | 2024 | 1409 | 0.620 |
Why?
|
Papillomavirus Infections | 2 | 2020 | 1616 | 0.610 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 2018 | 64 | 0.610 |
Why?
|
Anthozoa | 1 | 2019 | 65 | 0.610 |
Why?
|
Alphapapillomavirus | 1 | 2020 | 218 | 0.580 |
Why?
|
Dermatomyositis | 1 | 2020 | 258 | 0.550 |
Why?
|
Eosinophilia | 4 | 2022 | 557 | 0.550 |
Why?
|
Herpes Simplex | 1 | 2020 | 465 | 0.540 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3093 | 0.510 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3215 | 0.500 |
Why?
|
Social Class | 1 | 2024 | 1993 | 0.490 |
Why?
|
Extremities | 1 | 2020 | 867 | 0.480 |
Why?
|
Herpesvirus 1, Human | 1 | 2020 | 739 | 0.470 |
Why?
|
Pandemics | 6 | 2023 | 8663 | 0.460 |
Why?
|
Adrenal Cortex Hormones | 2 | 2022 | 1878 | 0.390 |
Why?
|
Cellulitis | 2 | 2024 | 208 | 0.380 |
Why?
|
Autoantibodies | 1 | 2020 | 2119 | 0.370 |
Why?
|
Vaccination | 2 | 2020 | 3369 | 0.370 |
Why?
|
Health Personnel | 1 | 2024 | 3337 | 0.360 |
Why?
|
Skin Ulcer | 2 | 2024 | 130 | 0.350 |
Why?
|
Soft Tissue Infections | 2 | 2022 | 168 | 0.340 |
Why?
|
Humans | 75 | 2024 | 761208 | 0.340 |
Why?
|
Health Services Accessibility | 3 | 2024 | 5425 | 0.330 |
Why?
|
Hospitalization | 10 | 2023 | 10707 | 0.310 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 26071 | 0.290 |
Why?
|
Inpatients | 7 | 2024 | 2545 | 0.280 |
Why?
|
Outpatients | 2 | 2024 | 1598 | 0.260 |
Why?
|
Blister | 2 | 2023 | 86 | 0.260 |
Why?
|
Micronutrients | 4 | 2022 | 381 | 0.250 |
Why?
|
Fatal Outcome | 2 | 2020 | 1838 | 0.250 |
Why?
|
Malnutrition | 2 | 2022 | 622 | 0.250 |
Why?
|
Ohio | 3 | 2020 | 322 | 0.250 |
Why?
|
Psoriasis | 2 | 2024 | 946 | 0.250 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 696 | 0.240 |
Why?
|
Retrospective Studies | 20 | 2024 | 80674 | 0.240 |
Why?
|
Xylazine | 1 | 2024 | 12 | 0.230 |
Why?
|
Skin Diseases, Infectious | 2 | 2021 | 76 | 0.230 |
Why?
|
Epidermal Cyst | 1 | 2024 | 64 | 0.230 |
Why?
|
Hospitals, University | 3 | 2020 | 565 | 0.220 |
Why?
|
Social Welfare | 1 | 2024 | 87 | 0.210 |
Why?
|
Ambulatory Care | 2 | 2024 | 2770 | 0.210 |
Why?
|
Biopsy | 5 | 2024 | 6781 | 0.210 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9566 | 0.210 |
Why?
|
Hamartoma | 1 | 2024 | 236 | 0.200 |
Why?
|
Male | 22 | 2024 | 360693 | 0.190 |
Why?
|
Adult | 19 | 2024 | 221119 | 0.190 |
Why?
|
Female | 25 | 2024 | 392544 | 0.190 |
Why?
|
Human papillomavirus 6 | 1 | 2021 | 16 | 0.190 |
Why?
|
Panniculitis | 1 | 2021 | 45 | 0.190 |
Why?
|
Carcinoma, Verrucous | 1 | 2021 | 27 | 0.190 |
Why?
|
Sweet Syndrome | 1 | 2022 | 58 | 0.190 |
Why?
|
Virus Activation | 2 | 2020 | 319 | 0.190 |
Why?
|
Condylomata Acuminata | 1 | 2021 | 75 | 0.190 |
Why?
|
Penile Diseases | 1 | 2021 | 45 | 0.190 |
Why?
|
Neuregulins | 1 | 2000 | 36 | 0.190 |
Why?
|
Permethrin | 1 | 2020 | 15 | 0.180 |
Why?
|
Dermatitis, Exfoliative | 1 | 2020 | 27 | 0.180 |
Why?
|
Biotin | 1 | 2022 | 251 | 0.180 |
Why?
|
Skin Diseases, Bacterial | 1 | 2021 | 67 | 0.180 |
Why?
|
Agrin | 1 | 2000 | 75 | 0.180 |
Why?
|
Ivermectin | 1 | 2020 | 46 | 0.180 |
Why?
|
Nasopharyngitis | 1 | 2020 | 10 | 0.180 |
Why?
|
Transcription Factors | 1 | 2020 | 12099 | 0.170 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2020 | 42 | 0.170 |
Why?
|
Dermatomycoses | 1 | 2020 | 48 | 0.170 |
Why?
|
Thiosulfates | 1 | 2020 | 53 | 0.170 |
Why?
|
Acrodermatitis | 1 | 2019 | 15 | 0.170 |
Why?
|
Middle Aged | 16 | 2024 | 220853 | 0.170 |
Why?
|
Groin | 1 | 2020 | 106 | 0.170 |
Why?
|
Prone Position | 1 | 2021 | 196 | 0.170 |
Why?
|
Receptors, Cholinergic | 1 | 2000 | 244 | 0.170 |
Why?
|
Scurvy | 1 | 2019 | 36 | 0.170 |
Why?
|
Necrosis | 1 | 2024 | 1610 | 0.170 |
Why?
|
Vitamin B Complex | 1 | 2021 | 299 | 0.160 |
Why?
|
Aged | 10 | 2024 | 169288 | 0.160 |
Why?
|
Acyclovir | 1 | 2020 | 267 | 0.160 |
Why?
|
Deficiency Diseases | 1 | 2019 | 74 | 0.160 |
Why?
|
Gonadal Hormones | 1 | 2019 | 30 | 0.160 |
Why?
|
Substance Abuse, Intravenous | 1 | 2024 | 529 | 0.160 |
Why?
|
Zinc | 2 | 2021 | 672 | 0.160 |
Why?
|
Cryotherapy | 1 | 2020 | 160 | 0.160 |
Why?
|
Selenium | 1 | 2021 | 416 | 0.160 |
Why?
|
Clinical Coding | 1 | 2020 | 181 | 0.160 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13632 | 0.150 |
Why?
|
Herpesviridae Infections | 1 | 2020 | 269 | 0.150 |
Why?
|
Chelating Agents | 1 | 2020 | 383 | 0.150 |
Why?
|
Hospitals | 5 | 2023 | 3881 | 0.150 |
Why?
|
Thrombophilia | 1 | 2021 | 306 | 0.150 |
Why?
|
Calciphylaxis | 1 | 2020 | 130 | 0.150 |
Why?
|
Neuromuscular Junction | 1 | 2000 | 405 | 0.150 |
Why?
|
Transsexualism | 1 | 2022 | 208 | 0.150 |
Why?
|
Administration, Topical | 1 | 2020 | 703 | 0.150 |
Why?
|
Diagnosis, Differential | 4 | 2024 | 12976 | 0.150 |
Why?
|
Length of Stay | 4 | 2024 | 6417 | 0.140 |
Why?
|
Opportunistic Infections | 1 | 2020 | 376 | 0.140 |
Why?
|
Sepsis | 2 | 2022 | 2585 | 0.140 |
Why?
|
Candida albicans | 1 | 2020 | 372 | 0.140 |
Why?
|
Remote Consultation | 1 | 2019 | 237 | 0.140 |
Why?
|
Immunoglobulin A | 1 | 2020 | 979 | 0.140 |
Why?
|
Hidradenitis Suppurativa | 1 | 2020 | 177 | 0.130 |
Why?
|
Neutropenia | 1 | 2022 | 885 | 0.130 |
Why?
|
Alopecia | 1 | 2021 | 412 | 0.130 |
Why?
|
Fever | 1 | 2024 | 1618 | 0.130 |
Why?
|
Critical Pathways | 1 | 2020 | 475 | 0.130 |
Why?
|
HIV Infections | 1 | 2023 | 17347 | 0.130 |
Why?
|
Health Literacy | 1 | 2022 | 444 | 0.130 |
Why?
|
Cysts | 1 | 2021 | 680 | 0.130 |
Why?
|
End Stage Liver Disease | 1 | 2020 | 352 | 0.130 |
Why?
|
Triage | 1 | 2023 | 985 | 0.130 |
Why?
|
Self-Injurious Behavior | 1 | 2022 | 566 | 0.120 |
Why?
|
Fluorouracil | 1 | 2020 | 1642 | 0.120 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 667 | 0.120 |
Why?
|
Bacteremia | 1 | 2020 | 978 | 0.110 |
Why?
|
Prednisone | 1 | 2018 | 1565 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2000 | 1624 | 0.110 |
Why?
|
Minority Groups | 1 | 2020 | 1201 | 0.100 |
Why?
|
Anti-Bacterial Agents | 4 | 2024 | 7407 | 0.100 |
Why?
|
Dietary Supplements | 2 | 2022 | 3410 | 0.100 |
Why?
|
Physician's Role | 1 | 2019 | 920 | 0.100 |
Why?
|
Pilot Projects | 2 | 2024 | 8642 | 0.090 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8519 | 0.090 |
Why?
|
Comorbidity | 3 | 2023 | 10516 | 0.090 |
Why?
|
Young Adult | 3 | 2024 | 59221 | 0.090 |
Why?
|
United States | 5 | 2020 | 72339 | 0.090 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2631 | 0.080 |
Why?
|
Algorithms | 2 | 2020 | 14025 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2244 | 0.080 |
Why?
|
Patient Readmission | 1 | 2023 | 3265 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1923 | 0.080 |
Why?
|
Societies, Medical | 1 | 2020 | 3923 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4574 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2478 | 0.070 |
Why?
|
Antiviral Agents | 1 | 2020 | 3048 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4190 | 0.070 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2021 | 2421 | 0.070 |
Why?
|
International Classification of Diseases | 2 | 2022 | 915 | 0.070 |
Why?
|
Clinical Laboratory Techniques | 2 | 2021 | 746 | 0.060 |
Why?
|
Physical Examination | 2 | 2022 | 1255 | 0.060 |
Why?
|
Hospital Mortality | 3 | 2023 | 5295 | 0.050 |
Why?
|
Tissue Culture Techniques | 1 | 2024 | 289 | 0.050 |
Why?
|
Language | 2 | 2022 | 1539 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9457 | 0.050 |
Why?
|
Internship and Residency | 1 | 2022 | 5885 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5333 | 0.050 |
Why?
|
Pantothenic Acid | 1 | 2021 | 17 | 0.050 |
Why?
|
Dapsone | 1 | 2022 | 56 | 0.050 |
Why?
|
Risk Factors | 4 | 2023 | 74239 | 0.050 |
Why?
|
Single-Blind Method | 1 | 2024 | 1577 | 0.040 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2020 | 66 | 0.040 |
Why?
|
Herpesvirus 7, Human | 1 | 2020 | 14 | 0.040 |
Why?
|
Administration, Cutaneous | 1 | 2022 | 713 | 0.040 |
Why?
|
Schwann Cells | 1 | 2000 | 196 | 0.040 |
Why?
|
Receptor, erbB-3 | 1 | 2000 | 142 | 0.040 |
Why?
|
Herpesvirus 6, Human | 1 | 2020 | 96 | 0.040 |
Why?
|
Delphi Technique | 1 | 2023 | 848 | 0.040 |
Why?
|
Vitamin K | 1 | 2021 | 313 | 0.040 |
Why?
|
Copper | 1 | 2021 | 365 | 0.040 |
Why?
|
Presynaptic Terminals | 1 | 2000 | 302 | 0.040 |
Why?
|
Vitamin A | 1 | 2021 | 612 | 0.040 |
Why?
|
Mouth Mucosa | 1 | 2021 | 432 | 0.040 |
Why?
|
Sex Reassignment Procedures | 1 | 2019 | 70 | 0.040 |
Why?
|
Ascorbic Acid | 1 | 2021 | 654 | 0.040 |
Why?
|
Demography | 1 | 2022 | 1641 | 0.040 |
Why?
|
Antigens, Differentiation | 1 | 2000 | 918 | 0.040 |
Why?
|
Head | 1 | 2023 | 922 | 0.040 |
Why?
|
Microscopy, Electron | 1 | 2000 | 2561 | 0.040 |
Why?
|
Vancomycin | 1 | 2020 | 503 | 0.040 |
Why?
|
Health Plan Implementation | 1 | 2019 | 336 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2000 | 2468 | 0.030 |
Why?
|
Comprehension | 1 | 2022 | 619 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12159 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 858 | 0.030 |
Why?
|
Cultural Competency | 1 | 2019 | 298 | 0.030 |
Why?
|
Placebos | 1 | 2020 | 1666 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2020 | 750 | 0.030 |
Why?
|
Hair | 1 | 2019 | 498 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1791 | 0.030 |
Why?
|
Educational Status | 1 | 2022 | 2510 | 0.030 |
Why?
|
Folic Acid | 1 | 2021 | 1323 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2000 | 1967 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2020 | 1076 | 0.030 |
Why?
|
Vulnerable Populations | 1 | 2019 | 706 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3134 | 0.030 |
Why?
|
Vitamins | 1 | 2021 | 1634 | 0.030 |
Why?
|
DNA, Viral | 1 | 2020 | 2195 | 0.030 |
Why?
|
Learning | 1 | 2022 | 1737 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 22140 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2020 | 22174 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2022 | 2756 | 0.020 |
Why?
|
Program Evaluation | 1 | 2019 | 2489 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2020 | 6067 | 0.020 |
Why?
|
Animals | 2 | 2019 | 168079 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2000 | 2553 | 0.020 |
Why?
|
Communication | 1 | 2024 | 3872 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2000 | 8164 | 0.020 |
Why?
|
Internet | 1 | 2022 | 3096 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9319 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2022 | 14675 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7804 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3253 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2000 | 4947 | 0.020 |
Why?
|
Rats | 1 | 2000 | 23704 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3354 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15721 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2022 | 39126 | 0.010 |
Why?
|
Quality of Life | 1 | 2021 | 13367 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41496 | 0.010 |
Why?
|
Prognosis | 1 | 2019 | 29687 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 24021 | 0.010 |
Why?
|
Signal Transduction | 1 | 2000 | 23416 | 0.010 |
Why?
|
Concepts
(238)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_